Blockade of intra-articular TNF in peripheral spondyloarthritis: Its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers

Joint Bone Spine

Volumn 80, Issue 2, 2013, Pages 165-170

  Fiocco, Ugo ^a   Sfriso, Paolo ^a   Oliviero, Francesca ^a   Lunardi, Francesca ^a   Calabrese, Fiorella ^a   Scagliori, Elena ^a   Cozzi, Luisella ^a   Di Maggio, Antonio ^a   Nardacchione, Roberto ^b   Molena, Béatrice ^a   Felicetti, Mara ^a   Gazzola, Katia ^a   Stramare, Roberto ^a   Rubaltelli, Léopoldo ^a   Accordi, Benedetta ^a   Costa, Luisa ^c   Roux Lombard, Pascale ^c,d   Punzi, Leonardo ^a   Dayer, Jean Michel ^e  

^a UNIVERSITY OF PADOVA   (Italy)

^b Abano Terme General Hospital   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Contrast enhanced magnetic resonance imaging; Intra articular TNF blockade; Peripheral spondyloarthritis; Synovial fluid biomarker; Synovial tissue biomarkers; Ultrasonography

Indexed keywords

C REACTIVE PROTEIN; CD31 ANTIGEN; CD45 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; KNEE DISEASE; MALE; MONONUCLEAR CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPINE RADIOGRAPHY; SPONDYLARTHRITIS; SYNOVIAL FLUID; SYNOVITIS; SYNOVIUM; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; SYNOVITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875526503     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.06.016     Document Type: Article

References (40)

1. Braun J., Sieper J. Ankylosing spondylitis. Lancet 2007, 369:1379-1390.
2. Baeten D., Kruithof E., De Rycke L., et al. Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients. Arthritis Rheum 2004, 50:2931-2941.
3. Kruithof E., De Rycke L., Vandooren B., et al. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006, 54:1795-1804.
4. Fisher B.A., Keat A. Should we be using intra-articular tumor necrosis factor blockade in inflammatory monoarthritis?. J Rheumatol 2006, 33:1934-1935.
5. Fiocco U., Punzi L. Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?. Joint Bone Spine 2011, 78:331-334.
6. Osborn T.G. Intra-articular etanercept vs saline in rheumatoid arthritis: a single injection double-blind placebo-controlled study. Arthritis Rheum 2002, 46 Suppl.:S518.
7. Bliddal H., Terslev L., Qvistgaard E., et al. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand J Rheumatol 2006, 35:341-345.
8. van der Bijl A.E., Teng Y.K., van Oosterhout M., et al. Efficacy of intra-articular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial. Arthritis Rheum 2009, 61:974-978.
9. Keen H.I., Bingham C.O., BradLey L.A., et al. Assessing single joints in arthritis clinical trials. J Rheumatol 2009, 36:2092-2096.
10. Fiocco U., Sfriso P., Nardacchione R., et al. Evaluation of the efficacy and safety of repeated intra-articular etanercept injections in resistant knee joint synovitis. Arthritis Rheum 2007, 56:S592.
11. Fiocco U., Sfriso P., Scagliori E., et al. Soft tissue changes induced by repeated serial intra-articular etanercept injections in the knee joints of patients with resistant knee joint synovitis. Arthritis Rheum 2008, 58:S588.
12. Singh R., Aggarwal A., Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 2007, 34:2285-2290.
13. Fiocco U., Sfriso P., Oliviero F., et al. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intra-articular tumor necrosis factor-alpha blockade in the knee joint. Arthritis Res Ther 2010, 12:R148.
14. Wright H.L., Bucknall R.C., Moots R.J., et al. Analysis of SF and plasma cytokines provides insights into the mechanisms of inflammatory arthritis and may predict response to therapy. Rheumatology (Oxford) 2012, 51:451-459.
15. Rudwaleit M., van der Heijde D., Landewé R., et al. The Assessment of Spondylo Arthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70:25-31.
16. Thompson P.W., Silman A.J., Kirwan J.R., et al. Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum 1987, 30:618-623.
17. Fiocco U., Ferro F., Vezzu M., et al. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept. Ann Rheum Dis 2005, 64:899-905.
18. Rhodes L.A., Grainger A.J., Keenan A.M., et al. The validation of simple scoring methods for evaluating compartment specific synovitis detected by MRI in knee osteoarthritis. Rheumatology 2005, 44:1569-1573.
19. Boesen M., Boesen L., Jensen K.E., et al. Clinical outcome and imaging changes after intra-articular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. J Rheumatol 2008, 35:584-591.
20. Keen H.I., Mease P.J., Bingham C.O., et al. Systematic review of MRI, ultrasound, and scintigraphy as outcome measures for structural pathology in interventional therapeutic studies of knee arthritis: Focus on responsiveness. J Rheumatol 2011, 38:142-154.
21. Song I.H., Althoff C.E., Hermann K.G., et al. Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI. Ann Rheum Dis 2009, 68:75-83.
22. Chizzolini C., Dayer J.M., Miossec P. Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?. Arthritis Res Ther 2009, 11:246.
23. van Kuijk A.W., Reinders-Blankert P., Smeets T.J., et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006, 65:1551-1557.
24. Assier E., Boissier M.C., Dayer J.M. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010, 77:532-536.
25. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-949.
26. Cohen T., Nahari D., Cerem L.W., et al. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271:736-741.
27. Goodman W.A., Levine A.D., Massari J.V., et al. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 2009, 183:3170-3176.
28. Baeten D., Kruithof E., van den Bosch F., et al. Immunomodulatory effects of anti-tumor necrosis factor-therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001, 44:186-195.
29. Kruithof E., De Rycke L., Roth J., et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondyloarthropathies. Arthritis Rheum 2005, 52:3898-3909.
30. Pontifex E.K., Gerlag D.M., Gogarty M., et al. Change in CD3 positive T cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single-centre, open-label study. Arthritis Res Ther 2011, 13:R7.
31. Appel H., Maier R., Wu P., et al. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011, 13:R95.
32. Moran E.M., Heydrich R., Ng C.T., et al. IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS One 2011, 6:e24048.
33. Cañete J.D., Pablos J.L., Sanmartí R., et al. Antiangiogenic effects of anti-tumor necrosis factor-alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004, 50:1636-1641.
34. Izquierdo E., Cañete J.D., Celis R., et al. Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. PLoS One 2009, 4:e8131.
35. Kennedy P.A., Ng C.T., Chang T.C., et al. TNF-blocking therapy alters joint inflammation and hypoxia. Arthritis Rheum 2011, 63:923-932.
36. Caproni M., Antiga E., Melani L., et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009, 29:210-214.
37. Kageyama Y., Ichikawa T., Nagafusa T., et al. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol Int 2007, 28:137-143.
38. Koczan D., Drynda S., Hecker M., et al. Molecular discrimination of responders and non-responders to anti-TNF-alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008, 10:R50.
39. Zaba L.C., Suárez-Fariñas M., Fuentes-Duculan J., et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. Allergy Clin Immunol 2009, 124:1022-1030.
40. Gottlieb A.B., Chamian F., Masud S., et al. TNF inhibition rapidLy down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005, 175:2721-2729.